30,000 volunteers - and counting!

Posted:
17
September 2004

Today we are celebrating after successfully recruiting our 30,000th clinical trial volunteer. This major milestone has been reached in just two and a half years, demonstrating that we continue to lead the market in volunteer recruitment.Wendy Galloway, head of Volunteer Recruitment, commented: “We are all delighted to have recruited 30,000 volunteers in such a short period of time, and I would like to thank everyone within our dedicated volunteer recruitment team for making this possible. I would also like to thank the hundreds of volunteers who participate in our trials every month — we appreciate that their full co-operation is pivotal to any study, which is why we make the time they spend staying in our wards as safe, comfortable and enjoyable as possible.”Our highly motivated volunteer recruitment team consistently recruits over 1,000 volunteers a month. We have an integrated sales and marketing approach to recruitment, including targeted advertising campaigns and our dedicated recruitment website www.trials4us.co.uk.Due to the increasing number of studies conducted by Richmond, the volunteer recruitment team is constantly building upon our impressive volunteer database to ensure that all study recruitment targets are met. The database encompasses a wide range of populations, for instance 14% of the database are healthy volunteers aged 60 years or above. We guarantee volunteer panels for all our clients. For more information visit our volunteer recruitment section.

Trials4us

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more